IKKalpha mediated NOTCH1 Activation Promotes Tumorigenesis via FOXA2 Suppression by Liu, Mo
Texas Medical Center Library
DigitalCommons@The Texas Medical Center
UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences
8-2012
IKKalpha mediated NOTCH1 Activation
Promotes Tumorigenesis via FOXA2 Suppression
Mo Liu
Follow this and additional works at: http://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Medicine and Health Sciences Commons
This Dissertation (PhD) is brought to you for free and open access by the
Graduate School of Biomedical Sciences at DigitalCommons@The Texas
Medical Center. It has been accepted for inclusion in UT GSBS
Dissertations and Theses (Open Access) by an authorized administrator of
DigitalCommons@The Texas Medical Center. For more information,
please contact laurel.sanders@library.tmc.edu.
Recommended Citation
Liu, Mo, "IKKalpha mediated NOTCH1 Activation Promotes Tumorigenesis via FOXA2 Suppression" (2012). UT GSBS
Dissertations and Theses (Open Access). Paper 261.
IKKα Mediated NOTCH1 Activation Promotes Tumorigenesis via  
FOXA2 Suppression 
 
By 
Mo Liu 
APPROVED: 
____________________________ 
Mien-Chie Hung, Ph.D., Supervisor 
_____________________________ 
Dihua Yu, M.D., Ph.D. 
______________________________ 
Elsa R. Flores, Ph.D. 
______________________________ 
Hui-Kuan Lin, Ph.D.  
______________________________ 
 Andrew Bean, Ph.D. 
APPROVED: 
___________________________________ 
DEAN, THE UNIVERSITY OF TEXAS 
HEALTH SCIENCE CENTER AT HOUSTON 
GRADUATE SCHOOL OF BIOMEDICAL SCIENCES 
IKKα Mediated NOTCH1 Activation Promotes Tumorigenesis via   
FOXA2 Suppression 
 
A 
DISSERTATION 
 
Presented to the Faculty of 
The University of Texas 
Health Science Center at Houston 
and 
The University of Texas 
M. D. Anderson Cancer Center 
Graduate School of Biomedical Sciences 
In Partial Fulfillment 
Of the Requirements 
For the Degree of 
 
DOCTOR OF PHILOSOPHY 
 
by 
Mo Liu, M.S. 
 
Houston, Texas 
August, 2012
 iii
 
ACKNOWLEDGEMENTS  
 
I would like to express my utmost appreciation to all those who have assisted me 
throughout my graduation studies. First, I would like to thank to my mentor, Dr. 
Mien-Chie Hung for accepting me to join his outstanding lab, for all his fully support 
and guidance, and taught me not only in scientific research but also all 
encouragement when I face difficulties and challenges. It goes without saying that 
these are going to benefit to my future career and life. Second, I would like to thank 
all of my committee members for their valuable advice and guidance, Dr. Dihua Yu, 
Dr. Elsa Flores, Dr. Andrew Beans, Dr. Michael Van Dyke, Dr. Peng Huang, Dr. 
Michelle Barton, Dr. Pierre McCrea and Dr. Hui-kuan Lin. Third, I would like to thank 
my friends and colleagues who have helped me throughout my graduate study, 
especially to Dr. Chun-Te Chen, Hong-Jen Lee, Dr. Weiya Xia, Dr.Dung-Fang Lee, 
Dr. Chia-Jui Yen and Dr. Jun-Mao Hsu. Last but not least, I would like give my 
appreciation to my parents and my all family for their encouragement and support. 
 
 
 
 
 
 
 
 iv
 
IKKα Mediated NOTCH1 Activation Promotes Tumorigenesisvia  
FOXA2 Suppression 
 
 
Publication No. _____________ 
 
 
 
Mo Liu 
 
Supervisory Professor: Mien-Chie Hung, Ph.D. 
 
 
 
Abstract 
Proinflammatory cytokine TNFα plays critical roles in promoting malignant cell 
proliferation, angiogenesis, and tumor metastasis in many cancers. However, the 
mechanism of TNFα-mediated tumor development remains unclear. Here, we show 
that IKKα, an important downstream kinase of TNFα, interacts with and 
phosphorylates FOXA2 at S107/S111, thereby suppressing FOXA2 transactivation 
activity and leading to decreased NUMB expression, and further activates the 
downstream NOTCH pathway and promotes cell proliferation and tumorigenesis. 
Moreover, we found that levels of IKKa, pFOXA2 (S107/ 111), and activated 
NOTCH1 were significantly higher in hepatocellular carcinoma tumors than in normal 
 v
liver tissues and that pFOXA2 (S107/111) expression was positively correlated with 
IKKα and activated NOTCH1 expression in tumor tissues. Therefore, dysregulation of 
NUMB-mediated suppression of NOTCH1 by TNFα/IKKα-associated FOXA2 
inhibition likely contributes to inflammationmediated cancer pathogenesis. Here, we 
report a TNFα/IKKα/FOXA2/NUMB/NOTCH1 pathway that is critical for 
inflammation-mediated tumorigenesis and may provide a target for clinical 
intervention in human cancer. 
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CHAPTER 1 INTRODUCTION 
 
1.1 Liver cancer and inflammation  
     Liver cancer is the third most common cancer in the world1. 90% liver cancer 
patients die within a year after diagnosis, and 5-year survival rate of liver cancer is 
only 6.9%2,3. In 2008, it was estimated that there were about 700,000 new cases of 
liver cancer worldwide, and a similar number of patients died as a result of this 
disease4-6. Nativity, residential enclave status, and neighborhood SES characterize 
Hispanics and Asians with significantly unequal incidence rates of liver cancer, 
implicating behavioral or environmental risk factors, including primarily associated 
with geography incidence rate risk factor chronic hepatitis B virus (HBV) and 
hepatitis C virus (HCV) infections, dietary aflatoxin exposure, alcohol-related 
cirrhosis, fatty liver disease, obesity, smoking, diabetes, and iron overload7,8.  
     It is not a surprise to see the tight correlation between liver inflammation and 
liver cancer. Back to early 1863, the founder of modern pathology, Dr. Rudolf 
Virchow suggested that “lymphoreticular infiltrate” reflected the origin of cancer at 
sites of chronic irritation9,10. It is the first time that people noticed the association 
between inflammation and cancer. Since then, the relationship between 
inflammation and cancer has been observed and studied for a long time. Now, the 
causal relationship between inflammation and cancer is more widely accepted with 
general molecular and cellular mechanisms underneath. One of typical examples is 
 2
extrinsic factors induced inflammatory or infectious conditions augment the risk of 
developing cancer at certain anatomical sites (for example, the liver)11-13. This 
extrinsic pathways converge resulting in the activation of transcription factors, like 
nuclear factor-κB (NF-κB), signal transducer and activator of transcription 3 
(STAT3) and hypoxia-inducible factor 1α (HIF1α), in tumour cells. These 
transcription factors coordinate the production of inflammatory mediators, including 
cytokines and chemokines. The proinflammtory cytokines and chemokines, such 
as tumor necrosis factorα (TNFα), multiple interleukin factors recruit and activate 
various leukocytes, most notably cells of the myelomonocytic lineage. The 
cytokines activate the same key transcription factors in inflammatory cells, stromal 
cells and tumour cells, resulting in more inflammatory mediators being produced 
and a cancer-related inflammatory microenvironment to enhance cell proliferation, 
cell survival, cell migration and tumor angiogenesis, thereby promoting tumor 
development14-16. However, the mechanism of how specific type of inflammation 
targets unique cancer markers to promote tumorigenesis in different tumor 
development stages is still obscure. Therefore, uncovering the mechanism 
involving in inflammation-cancer process for further therapeutic and prevention 
study is urgently needed, and the identification of the molecules associated with 
inflammation-mediated tumorigenesis will provide a novel strategy for development 
anticancer or prevention agents.  
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1.2 TNFα pathway and cancer 
 
     The microenvironment surrounding tumors comprise with couple distinct 
types of cells, including fibroblasts, endothelial cells, and inflammatory cells. And a 
neoplastic clonal cell population exists in stromal and infiltrating inflammatory cells 
to provide sustenance and facilitate the potential metastatic process of the 
malignant cell 17,18. One of the crucial aspects of the tumor micro-environment is the 
cytokine-mediated communication between the tumour and stromal cells19. Tumor 
necrosis factor-α (TNF-α), as one of most important inflammatory factor, have large 
amount of activities to permit cell-cell communication and involve in 
inflammation-associated tumorigenesis 20.  
     The classical signaling pathway responded to TNFα is NF-κB pathway via 
TNFR1. TNFR1 engagement leads to recruitment of the adaptor molecule TRADD, 
which subsequently recruits the signaling proteins TRAF2 and RIP1. TRAF2 
mediates recruitment of the IKK complex.TAB2 and TAB3 interact with TRAF2 and 
TAK1 resulting in the activation of TAK1. TAK1-phosphorylated IKKβ is on its 
activation loop. Active IKK phosphorylates IκBs on conserved serines, triggering 
their degradation through β-TRCP ubiquitin-proteasome proteolytic system and 
release of bound NF-κB dimers, which translocate to the nucleus to drive gene 
transcription which associates with tumorigenesis 21.  
Accumulated evidences show that he low-dose, chronic TNFα production is a 
feature of many tumor cells22. For example, the tumor-promoting role of TNFα was 
 4
similarly investigated in models of hepatic carcinogenesis. TNFRI-/- mice displayed 
reduced oval cell (hepatic stem cell) proliferation during the pre-neoplastic phase of 
liver carcinogenesis, correlating with fewer tumours than wild-type mice23. In 
addition, dysregulation of TNFα-IKK-NF-κB pathway is usually found in many human 
cancers. In Barrett’s esophageal adenocarcinoma and hepatoma, TNFα-IKK-NF-κB 
pathway is upregulated24,25; Mutation of CYLD induced constitutive activation of NF-κB 
occurs in cylindromatosis patients26-28; couple of mutations or loss-fuction IκB are 
dected in couple of cancer types, including colon cacner and breast cancer29-33. These 
pathological findings indicate the clinical relevance of TNFα signaling pathway in 
human cancer development. 
 
1.3 Independent Role of IKK subunits to NF-κB pathway 
 
     IKKα and IKKβ are major downstream serine/threonine kinases which have 
multiple functions dependent and independent on the NF-κB pathway. Previous 
study show that NF-κB-independent activities induced by TNFα34-40, For example, 
independent IKKβ positively regulate inflammation linked tumorgenesis and 
angiogenesis in several cancer types41-43.  
     It has also been reported that IKKα can be activated by TNFα treatment 
independently of IKKβ. For example, two Nature papers, published side-by-side, 
showed that IKKα, in response to TNFα, translocates from the cytoplasm to the 
nucleus and phosphorylates histone H3 to regulate transcription of target genes44,45. 
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In addition to histone H3, we also reported that IKKα is able to phosphorylate CBP 
and switches CBP binding preference from p53 to NF-κB upon TNFα stimulation 46. 
These TNFα-induced IKKα activities are independent of IKKβ. There are several 
reports that strongly support the idea that IKKα is able to contribute to tumor 
development independently of NF-κB. For instance, the nuclear function of IKKα 
has also been implicated in prostate cancer metastasis by inhibiting the expression 
of the tumor suppressor, Maspin, in mouse model47. Moreover, IKKα is able to 
phosphorylate and regulate ER, AIB1, CYCLIN D1, and β-CATENIN in cell 
proliferation48-52. Briefly, IKKα can increase cyclin D1 expression by 
phosphorylating and activating the estrogen receptor-α and SRC-3 on the cyclinD1 
promoter as well as phosphorylate cyclinD1 directly as a feedback loop. These 
activities contribute to oncogenic effects. These findings suggest that IKKα has the 
unique ability in regulating versatile physiological and pathological functions, which 
are independent of NF-κB.  
 
1.4 Forkhead Box Protein (Fox) and Cancer  
 
     Fox proteins are super transcriptional regulator family that is evolutionarily 
conserved. This family defined by a unique DNA-binding domain (DBD) called the 
forkhead box or winged helix domain53,54. Members of this family bind DNA as 
monomers and regulate downstream target gene expression. The N terminus and 
C terminus contain transactivation domains whose function is regulated at the level 
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of phosphorylation55. So far, there are 17 Fox gene subfamilies, with at least 41 
genes identified in humans56,57. Fox proteins play important roles in a wide 
spectrum of biological processes, including metabolism, development, migration 
and cell cycle events58-62. Since Fox proteins control these essential homeostatic 
processes, the fact that losing or gaining of their functions alter cell fate and lead to 
tumorigenesis is in expectation. For example, in FoxA family, which shows a 
unique tissue-specific expression pattern, FoxA1 is essential for differentiation of 
epithelial cells in normal prostate, while prostate of FOXA1 knockout mice show 
hyperplastic lesions63,64; Overexpressed FoxA2 act as a key regulator in colon liver 
metastasis65. Except FoxA, several Fox subfamilies, such as FoxO, FoxP and 
FoxM are verified to link to tumorigenesis and the progression of certain 
cancers66-70.  
     Post translational modification, such as phosphorylation, acetylation and 
ubiquitination regulate Fox proteins activities. One of most clear example is 
FoxO3A. Several upstream kinases including Akt, JNK, CDK2 and IκB kinase (IKK) 
phosphorylate FoxO3A to induce its nuclear export and degradation. Deregulation 
of these kinases normally happen in tumors and contribute to tumorgenesis71-74. 
For example, disruption of IKK affects chromatin remodeling and NFκB signaling. 
Moreover, IKK has been shown to physically bind to and phosphorylate FoxO3A in 
tumor, and cytoplasmic FoxO3A correlates with the expression of IKKβ in many 
tumors and associates with poor prognosis in breast cancer72. Recent studies also 
show that insulin-induced FoxA2 phosphorylation by Akt promotes FoxA2 nuclear 
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exclusion, inactivates downstream target genes and unrestrains hepatic 
gluconeogenesis in type 2 diabetes, a disease strongly associated with cancers. 
Not only phosphorylation, acetylation and mono-ubiquitylation of Fox proteins play 
critical part in Fox regulated cancers. For example, FoxP3 suppresses of target 
gene expression involving a histone acetyltransferase–deacetylase complex75,76.  
     Deregulation of Fox factors can promote tumorigenesis by favoring 
proliferation and survival through the repression or induction of gene expression. 
For example, FoxO3a regulate FasL and p27 transcription77,78, FoxA2 is a well 
known regulator of GATA3 gene.79,80 The advent of chromatin immunoprecipitation 
coupled with microarray technology (ChIP-chip) brings larger scale of views of Fox 
transcriptional regulatory functions than which on traditional gene-to-gene basis81-85. 
Recently, genome-wide ChIP-sequencing experiments, which can detect 
transcription factor binding in any genomic region accurately, are used in FoxA2 to 
screen its downstream target genes in adult mouse liver. A large number of novel 
Foxa2 binding targets are reported for the first time, including both tumor suppress 
genes and well known oncogenes, such as fgf1, numb, and dlk186,87.    
     Based on our so far knowledge of Fox family, therapies that indirectly target 
Fox factors through cofactors or repressors of Fox, or direct target Fox by 
modifying the post-translational regulation of Fox factors, may enable a shift in 
Fox-induced gene expression, and change aberrantly regulated Fox proteins 
functions. Based on cooperativity with other regulatory factors, redundancy and 
tissue-specific roles of Fox proteins, Fox family proteins targeted drugs are 
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promising to have lower toxicity and higher tissue specificity. In clinical, some Fox 
family proteins are used, or have potential to be used, as both indirect and direct 
targets88. Breast carcinoma chemotherapeutic drugs pacliaxel activates JNK, which 
modulate the stability of FoxO3A by phosphorylation DBD of FoxO3A so that 
blocks tumorgenetic cascades regulated by FoxO3A89,90. FoxA1 as a marker for 
luminal subtype A breast cancer is also a good therapeutic candidate91. (Fig1) 
 
 
 
 
 
 
 
 
 
 
Fig 1 FOX proteins work as therapeutic targets in clinic.FOXM1 are used in HCC 
and Osteosarcoma; FOXO3A are used in both breast cancer and melanoma; 
FOXP3 are also used in melanoma via vaccination. 
 
1.5 NOTCH pathway and its role in cancer 
 
The discovery of a notch on wings of Drosophila melanogaster in 1914 is the 
first time NOTCH gene get noticed 92. With later one century studies, researchers 
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are opening the door to an ever-widening understanding of Notch family and 
related signalings which controlled multiple cellular processes, influence cell fate 
decision.  
     The Mammalian Notch family has four members, NOTCH1, NOTCH2, 
NOTCH3 and NOTCH4 93. The map of NOTCH signaling is not fully clear, but the 
general scheme is accepted. NOTCH signaling is initiated by the binding of 
NOTCH ligands with NOTCH receptors. After S1 cleavage of NOTCH precursor, 
mature NOTCH which comprises with two subunits, ECD (extracellular domain) 
and ICD (intracellular domain), changes its conformation, leading to S2 cleavage 
site exposure. S3 cleavage mediating by γ-secretase complex follows with S2 
cleavage consequently. The S3 cleavage results in the release of NICD from cell 
plasma membrane and translocation of NICD to nucleus. Major function of nuclear 
NICD is to mediate the conversion of the CBF1–Su(H)–LAG1 (CSL) repressor 
complex into a transcriptional activation complex, therefore initiates a 
transcriptional cascade to activate or repress target genes, including p21, Myc and 
HES and HEY family94-96. 
 
     The first role of NOTCH found in human cancer is to be an oncogene in 
T-ALL. Most of T-ALL cases have activating mutation of Notch1, which leads to 
constitutive activating of Notch pathway to promote tumorigenesis97. Comparing to 
causative role of Notch in T-ALL, the role of Notch signaling in solid tumors is 
vague. The status of The Notch signaling is highly dependent on the spatial and 
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temporal context of Notch activation and the status of other signaling pathways in 
the cells as well98.  
  
      
Several processes, including proteolysis, glycosylation, ubiquitylation and 
phosphorylation99, control Notch activation. Ligands overexpression, abnormally 
activated receptors or dysregulation of negative regulators may lead to aberrant 
activation of the Notch pathway100 Some of these circumstance are deregulated in 
cancers, resulting in aberrant Notch signaling101-103. 
NUMB and NUMB-like proteins function as signalling inhibitors for Notch by 
targeting the membrane-bound Notch for degradation following activation104. Loss 
of NUMB has been detected in over 50% percent of breast carcinoma105, and 
possibly results in the stabilization and hyperactivation of Notch. In addition, 
NUMB binds to p53 and MDM2 to prevent ubiquitylation of p53106. Thus, loss of 
NUMB in a large proportion of breast cancers can result in increased Notch activity 
and loss of p53 tumor suppressor function, resulting in an aggressive tumor 
phenotype with poor prognosis. 
     In contrast to its oncogenic actitives in multiple cancer types, Notch has been 
proved as a tumor suppressor in come cancer types as well. This tumor suppressor 
activities is worked as a result of crosstalk with other signaling pathways, which 
decrease cell proliferation, increase apoptosis or cellular differentiation107. For 
example, NOTCH could block WNT signaling to suppress tumorgenesis thereby 
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driving cells toward a more differentiated phenotype108 . 
 
     The knowledge of the extensive crosstalk of the Notch pathway with other 
pathways such as the epidermal growth factor receptor (EGFR) pathway, WNT 
pathways, could prove useful in developing combinatorial cancer therapies109. 
 
1.6 Statement of problem, hypotheses and project goals 
HCC is a typical tumor on a background of inflammation mainly triggered by 
exposure to infectious agents (hepatotropic viruses, inflammatory cytokines). In the 
past twenty years, many studies unfold significant alterations of different cytokines 
and their cascades in liver cirrhosis and HCC. However, the molecular links 
between inflammation and cancer progression are still remaining contradiction and 
not completely known.  
In previous studies, TNFα tumor promoting effects were found in several 
genetic mouse model of inflammation-related carcinogenesis through activating the 
key inflammatory transcriptional regulator NF-κB. Contrarily, hepatocyte-specific 
deletion of IKKβ gene or ablation of IKKγ/NEMO leads to the spontaneous 
development of HCC110-113. These phenomena indicate that other cascades, other 
than traditional NF-κB, are involved in TNFα induced liver cancer. Based on our 
previous research that IKKα/IKKβ can independently regulate downstream 
cascades to lead tumorgenesis and angiogenesis by phosphorylating Fox family, 
an interesting question is rising, whether IKKα/IKKβ dependent Fox cascades play 
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critical role in inflammation-induced liver cancer? If yes, which Fox is the player? 
In addition, in search of mechanisms that may be involved in TNFα-mediated 
tumorgenesis, the previous study showed that controversial roles of NF-κB in 
TNFα-mediated liver cancer in several genetic mouse models, thus it is still not 
clear whether IKKα/β has a role independent to NF-κB in the TNFα-mediated 
tumorgenesis. Preliminary data showing that in HCC patients, p-IKK expression 
has positive correlation to activated NOTCH1 expression. Therefore, it is possible 
that there are other NF-κB-independent pathways involved in TNFα-mediated NOTCH1 
production and tumorigenesis. We hypothesize that TNFα induces NOTCH1 activation 
through IKK-mediated phosphorylation of FOX protein, therefore increase of NOTCH1 
pathway activation, finally leading to tumorigenesis. 
  
CHAPTER 2 MATERIALS AND METHODS 
2.1 Cell culture  
Human hepatocellular carcinoma cancer cell lines (Hep3B, Huh-7, and HepG2), 
human embryonic kidney cell lines (HEK-293 and HEK-293T) and mouse 
embryonic firbroblasts (Ikkα-/-, Ikkβ-/-) were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM)/F12 medium supplemented with 10% fetal bovine serum. For 
transient transfection, cells were transfected with DNA by either Lipofectamine with 
Plus reagent or electroporation. 
2.2 Plasmids, antibodies, and chemicals 
We constructed Myc-FOXA2- and GFP-FOXA2-expressing plasmids by 
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inserting hFOXA2 complementary DNA (cDNA) into pcDNA6 and pCMV-EGFP 
vectors containing the Myc and GFP tags, respectively. We generated the 
GST-FOXA2-expressing plasmid by subcloning the FOXA2 fragment into the 
pGEX-6P-1 GST vector. Different mutant forms of the FOXA2 construct were 
generated by subcloning the FOXA2 fragment into pcDNA6 and pCMV-EGFP 
vectors. Mutants were generated using the QuikChange Multi Site-Directed 
Mutagenesis Kit (Stratagene). The FOXA2 and mutant expression plasmids were 
constructed into retroviral pBABE-Puro and pBABE-GFP vectors for retroviral 
infection and expression. 
  Antibodies against FLAG (F3165, Sigma), Myc (11667203001, Roche), 
IKKα (sc-7606, Santa Cruz), IKKβ (sc-8014, Santa Cruz), IκBα (9242S, Cell 
Signaling Technology), TNFα (Santa Cruz Biotechnology, SC-8301), IκBα (Santa 
Cruz Biotechnology, SC-371), IKKγ (Santa Cruz Biotechnology, SC-8330), RHEB 
(Santa Cruz Biotechnology, SC-6341), GAPDH (Santa Cruz Biotechnology, 
SC-20357), NOTCH1 (NICD) (sc-32745, Santa Cruz Biotechnology), 
pIκBα(S32/S36) (Cell Signaling Technology, 9246),NUMB (ab14140, Abcam), 
FOXA2 (ab60721, Abcam), p-IKKα(S176/180) (2697, Cell Signaling), α-tubulin 
(T-5168, Sigma), and actin (A2066, Sigma) were purchased from the indicated 
suppliers. Antibodies to the S107/111 phosphorylation sites of FOXA2 were 
generated at China Medical University. Synthetic phosphorylated peptides 
representing portions of FOXA2 around both S107 and S111 were used as 
antigens for producing antibodies. 
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TNFα was purchased from Sigma, and Bay (43-9006) and SCI34 were 
purchased from CalBiochem. Full-length recombinant GST-IKKα and His-IKKβ 
proteins were purchased from EMD Millipore. The liver tumor tissue array was 
purchased from US Biomax. 
 
2.3 siRNA 
Hep3B cells or Huh-7 cells were transfected with IKKα ON-TARGETplus siRNAs 
(LQ-003473-00-0002), NUMB ON-TARGETplus siRNAs (LQ-015902-00-0002), 
NOTCH ON-TARGETplus siRNAs (LU-007771-00-0002), or control SMARTpool 
siRNA (Upstate Biotechnology, D-001206-13-05) by lipofectamine with plus reagent 
and lysed 72 h after transfection. 
 
2.4 Transfection 
For transient transfection, cells were transfected with DNA by either SN 
liposome (59), lipofectamine with plus reagent, or electroporation using a Nucleofector 
1 device (Amaxa) with electroporation buffer (137 mM NaCl, 5 mM KCl, 0.7 mM 
Na2HPO4, 6 mM glucose, and 20 mM HEPES, pH 7.0). To investigate the effects of IKK 
on p-FOXA2 (Ser107/111), or NOTCH1 activation, the transfected cells were 
serum-starved overnight and extracted directly or after stimulation with TNFα (20ngl/ml), 
for 30 min or 24h. 
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2.5 In vitro pull-down assay 
Recombinant IKKα proteins and IKKβ proteins (EMD Millipore 21233; Upstate 
Biotechnology, 14-485) were incubated with in vitro transcription and translation lysates 
of myc-tagged TSC1, which was produced using a TNT coupled reticulocyte lysate 
system (Promega), in binding buffer (25 mM Tris-HCl, pH 7.5, 125 mM NaCl, 1 mM 
phenylmethylsulfonyl fluoride, 1 µg of leupeptin/ml, 1 µg of aprotinin/ml, and 1 µg of 
pepstatin/ml) for 1 h at 4°C. Rabbit IgG antibody (rIgG) or anti-IKKβ antibody was then 
added and incubation was continued at 4°C overnight. The resulting 
immunocomplexes were precipitated with protein A-Sepharose beads (Roche) at 
4°C for 4 h and washed extensively with Tris-buffered saline, and the bound 
proteins were eluted with sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis sample buffer and then analyzed by Western blotting. 
 
2.6 Immunoprecipitation and immunoblotting 
Cells were lysed in RIPA-B buffer (20 mM Na2HPO4 [pH 7.4], 150 mM NaCl , 
1% Triton X-100) with protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 5 
mM NaF, 2 mM sodium orthovanadate, 3µg/ml aprotinin, and 750µg/ml 
benzamidine). For immunoprecipitation, the samples were precleaned with either 
protein A or protein G agarose for 1 hr at 4 oC. Precleaned cell lysates were 
Proteins were immunoprecipitated by indicated antibodies for overnight at 4 oC, 
incubated with either protein A or protein G agarose for 3 hr at 4 oC, washed 
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ice-cold RIPA-buffer with protease inhibitors four times, resolved by SDS-PAGE, 
and transfer to PVDF membranes. For immunoblotting, membranes were blocked 
with TBST buffer (10 mM Tris-HCl (pH 7.9), 150 mM NaCl, and 0.05% Tween 20) 
with either 5% BSA or 5% skim milk, incubated with indicated primary antibodies, 
subsequently incubated with HRP-conjugated secondary antibodies and detected 
by ECL (Amersham Biosciences). 
 
2.7 In vitro kinase assays 
Briefly, 80% confluent Hep3B cells were serum starved for 16 h and then 
treated with/ or without 20ng/ml TNFα for 30 min. The cells were lysed and 
immunoprecipitated with  either anti-IKKα antibodies and analyzed by in vitro 
kinase assay using the purified GST-FOXA2 as substrates, respectively, and 
incubate at 30°C for 30 min in  the presence of 50 mM ATP in a kinase buffer with 
5 µCi [ -32P]ATP. Reaction products were subjected to SDS-PAGE and analyzed by 
autoradiography. 
 
2.8 Identification of in vivo phosphorylation sites by mass spectrometry 
After protein gel electrophoresis, bands corresponding to FOXA2 
phosphorylated by IKKα in vivo were identified, excised from gels, and subjected to 
tryptic digestion. After being isolated by immobilized metal affinity chromatography, 
the enriched phosphopeptides were analyzed by micro-liquid 
chromatography/tandem mass spectrometry.  
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2.9 Real-Time PCR 
Primer sequences used to quantify real-time PCR were as follows: Hey2: 
5′-AAACAAGGATCTGCAA-3′ and 5′-CGGAATCCTATGCTCATGAA-3′; Hey1: 
5′-TATCTGAGCATCATTGAA-3′ and 5′-TGTGCGGGTGATGTCCGAA-3′; p21: 
5′-GTGAAGGCTGTGTCTTC-3′ and 5′-TACAGATTTTGTGTGCTCT-3′; p27: 
5′-AATTTCGATTTTCA-3′ and 5′-CTTGCAGGCACCTTTGGGGG-3′; Hes6: 
5′-ATCAACGAGAGCCTG-3′ and 5′-CACTGGATGTAGCCGGCAGCGAA-3′. 
 
2.10 ChIP and Re-ChIP Assay 
Primer sequences used for ChIP-PCR were as follows: NUMB: 
5′-AATGAAATTGGATGCATTGAGACCA-3′ (forward) and 
5′-AAGCTTATCTCTGCTAGCTTTATTCA-3′ (reverse). GAPDH promoter was used 
as a negative control. 
 
2.11 Anchorage-Independent Growth Assay 
Briefly, the cell-growth matrix consisted of base agar and top agarose in six-well 
culture plates. The base layer (1.5 ml) contained DMEM/F12 medium, 10% FBS, 
and 0.5% agar. The top layer (1.5 ml) contained DMEM/F12 medium, 10% FBS, 
0.35% agarose, and the suspension of cells (5 × 103). The foci were counted after 3 
weeks. The modifications used for retrovirus-infected Hep3B cells are as follows: 
retrovirus-infected cells (5 × 104) were mixed with 0.5% agarose and poured onto a 
bed of 1% agar. Both the top and the bottom layers were prepared in DMEM/F12 
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medium with 10% FBS. 
 
2.12 Immunohistochemical Staining 
Briefly, human histoarrays of multiple cancerous tissues and human liver 
cancer tissues primary tumor specimens of HCC, colon, lung, and prostate cancer 
(IMH-365, US Biomax) were incubated with antibodies directed against p-IKKα or 
NICD (activated NOTCH1), detected with biotin-conjugated secondary antibody 
and avidin–peroxidase, and visualized by aminoethylcarbazole chromogen. 
Images were analyzed by ACIS (Dako). The samples were divided into two groups 
according to staining intensity: low (+/−) and high (+/+).The human liver primary 
tumor samples for Western blotting were received from Gaoxiong Medical Shool.. 
Fisher’s exact test and Spearman rank correlation were used for statistical analysis; P 
< 0.05 was considered statistically significant. According to histologic scoring, the 
intensity of staining was ranked into four groups: high (score 3), medium (score 2), low 
(score 1), and negative (score 0). The immunoreactivities for pIKK, NOTCH1 were 
semiquantitatively scored using a well-established immunoreactivity score system in 
which immunoreactivity score was generated by incorporating both the percentage of 
positive tumor cells and the intensity of staining. 
 
2.13 Mouse Model for Tumorigenesis 
We performed the tumorigenesis assay for retrovirus-infected cells with both 
a liver cancer subcutaneous mouse model and an orthotopic mouse model, which 
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has been described elsewhere. Cells were injected subcutaneously. After tumors 
reached 2–3 mm in diameter, tumors were harvested, dissected into small pieces 
(1*1*1 mm3), and transplanted into the livers of new mice (n = 5 per group). TV was 
calculated according to the formula described by Yaguchi et al.: TV = 0.5 3 length * 
width2. Animal experiment protocol number is approved by by the UT MD Anderson 
Cancer Institutional Animal Care and Use Committee under protocol number ACUF 
06-87-06139. Thirty patient samples are from National Cheng-Kung University 
Hospital. Thirty patients admitted to National Cheng-Kung University Hospital with 
HCC who received curative surgery between January 1, 2003, and December 31, 
2006, were enrolled, and National Cheng-Kung University Hospital Institutional 
Review Board approved the protocol. 
 
2.14 Statistical Analyses 
Statistical analyses were performed with Student’s t test, Spearman’s rank 
correlation test, or Pearson’s chi-square test as indicated. p < 0.05 was considered 
statistically significant. R2 > 0.5 was considered statistically correlated. 
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CHAPTER 3 
Phosphorylated IKK expression positively correlates with activated NOTCH1 
expression and high HCC tumor grade 
It is well known that both TNFα triggered signal pathways and NOTCH1 signling 
are critical to tumor cell proliferation and tumorigenesis in different cancer types. 
However, the critical underneath molecular mechanism linking these two pathways 
in hepatocellular carcinoma (HCC), especially inflammation associated 
hepatocellular carcinoma is not clear. To address a potential crosstalk between 
these two pathways in inflammation-associated HCC tumorigenesis, we examined 
the expression level of p-IKK, which is an important downstream kinase of TNFα, 
and the level of intracellular domain of NOTCH1, which is considered as activated 
NOTCH1 in 100 human primary HCC tumor specimens by immunohistochemical 
(IHC) staining. In 100 specimens, 47 of them were detected with high p-IKK 
expression, and 27 of which showed high NICD expression, indicating a significant 
positive correlation between p-IKK and NICD (p = 0.003, Figures 2A and 2B). In 
addition, both p-IKK and NICD had higher expression levels in higher-grade tumors 
(Figures 3A and 3B). To determine whether this relationship holds in other cancers, 
we examined human primary tumor specimens of colon, lung, and prostate cancer 
by IHC staining. Similar to our finding in liver tumors, we also found a positive 
correlation between p-IKK and NICD (see Figure 4) 
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Fig 2. Clinic Correlation between p-IKK and NICD 
 
(A) Correlation between levels of p-IKKα/β and activated NOTCH1 (NICD) in 100 
human primary HCC tumor specimens stained with antibodies specific to NICD and 
p-IKK (P = 0.003, Pearson’s chi-square test). 
 
(B) Two representative specimens from (A); arrows point to p-IKK and NICD. 
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Fig 3 Clinic correlation between p-IKK/NICD and tumor grade 
(A) Correlation between tumor grade and p-IKK expression. High p-IKK expression 
correlated significantly with higher tumor grade (P = 0.035, Pearson’s chi-square 
test). 
(B) Correlation between expression of p-IKK, NICD and tumor grade. High NICD 
expression correlated significantly with higher tumor grade (P = 0.01, Pearson’s 
chi-square test). 
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Fig 4 Clinic correlation between p-IKK and NICD in multiple cancer types 
Association between levels of p-IKKα/β (p-IKK) and activated NOTCH1 (NICD) in 
human primary tumor specimens of colon, lung, and prostate cancer stained with 
antibodies specific to NICD and p-IKK (P = 0.024, Pearson’s chi-square test). 
 
 
NOTCH
Total
Low
(+/-)
High
(+/+)
p-IKK Low 11 3 14
High 6 10 16
Total 17 13 30
P=0.024
Tumor tissues of 
multiple cancer types
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CHAPTER 4 IKKα is required for TNFα-induced NOTCH1 activation 
The clinical positive correlations between p-IKK and NICD raise a question in 
our mind: whether TNFα/IKK might upregulate NICD expression. To validate the 
relationship between IKK and NICD expression, we detected NOTCH1 intracellular 
domain, which is an activated form of NICD in mouse embryonic fibroblasts (MEFs) 
treating with TNFα (Figure 5). We found that after TNFα treatment, NICD 
expression in MEFs increase (Figure 5, top), which indicates that NOTCH1 
activation was increased upon TNF stimulation. To further investigate which 
components of IKK complex regulates NICD expression, wild-type (WT), IKKα–/–, 
and IKKβ–/– MEFs were treated with TNFα and compared their NICD expression 
level by westernblotting assay. The NICD level in IKKα–/– MEFs was substantially 
lower than in WT MEFs (Figure 5, bottom; compare lanes 1 and 2). Re-expression 
of IKKα in the IKKα–/– MEFs rescued NICD expression (Figure 8, bottom; compare 
lanes 2 and 3). However, re-expression of IKKβ could not affect the NICD level in 
IKKβ–/– MEFs (Figure 5, bottom; compare lane 1 with lanes 4 and 5). Together, 
these results indicate that IKKα, but not IKKβ, is necessary components in 
TNFα-induced NICD expression, suggesting that TNFα may stimulate NOTCH1 
activation through an IKKα-dependent pathway. 
To further confirm that IKKα is required for TNFα-mediated increase of NICD 
expression, a RBP-Jk reporter luciferase assay, which could monitor the activity of 
NOTCH1 signal transduction pathways in cultured cells by showing activities of two 
NOTCH1 downstream enzymes, was used as a tool to detect NOTCH1 activity. 
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IKKα expression was detected by western blot analysis to make sure IKKα was 
knocked down by siRNA (Figure 6, top). RBP-Jk reporter luciferase assay showed 
the similar results that NOTCH1 is activated by TNFα stimulation and such 
activation was that blocked by knocking down IKKα (Figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 26
Fig 5 IKKα is required for TNFα-induced NOTCH1 activation  
 
Top: WT MEFs were treated with or without TNFα (20 ng/ml) for 24 h, and cell 
lysates were subjected to western blot analysis for NICD expression.  
 
Bottom: IKKα and IKKβ were transfected into IKKα–/– MEFs and IKKβ–/– MEFs, 
respectively. After treatment with TNFα (20 ng/ml) for 24 h, cell lysates were 
subjected to western blotting. Lysates from MEFs without TNFα treatment served 
as control. α-Tubulin was used as loading control.
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Fig 6 NOTCH1 activity was blocked by IKKα knocking down 
 
RBP-Jk Luc and IKKα siRNA were transfected into Hep3B cells for 48 h. After 
transfection, WT and IKKα-knockdown Hep3B cells were treated with TNFα for 24 
h. Cell lysates were subjected to western blotting and luciferase reporter assay. 
Cells were transfected with nontargeting siRNA as control. Error bars represent SD 
(n = 3). * indicates, P < 0.05. 
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CHAPTER 5 NUMB suppression involves in TNFα induced NOTCH1 
activation 
 
After we know TNFα/IKKα regulates NOTCH1 activation, we are trying to 
know how what is the regulator in TNFα/IKKα induced NOTCH1 activation. As 
NUMB is known to atagonist NOTCH1 activation through degradation 
membrane-bounded NOTCH1 intracellular domain, we first tested whether NUMB 
expression level changed in the process of TNFα/IKKα-mediated NOTCH1 
activation. We found that TNFα treatment upregulated NICD expression and at the 
same time, NUMB expression level decreased in both Huh-7 and Hep3B in HCC 
cell lines (Figure 7A). Consistent with our results that only IKKα, but not IKKβ, 
involves in TNFα/IKKα regulates NOTCH1 activation, ectopic expression of IKKα 
but not IKKβ increased NICD expression and diminished NUMB expression as well 
(Figure 7B). In addition, blocking IKKα expression by siRNA knocking down 
recovered TNFα-mediated NUMB downregulation and subsequent impaired 
TNFα-mediated NOTCH1 activation (Figure 8A, compare lanes 2 and 4). 
Knockdown of both IKKα and NUMB restored NICD expression (Figure 8A, 
compare lanes 4 and 6), suggesting that TNFα/IKKα-mediated NOTCH1 activation 
involves NUMB downregulation. MEFs and IKKα–/– MEFs were used to further 
analyzed the relationships of IKKα, NUMB, and NICD. Higher NUMB expression 
and consistently lower NICD expression were found in IKKα–/– MEFs than in WT 
MEFs (Figure 8B). Rescure IKKα by overexpressing IKKα in IKKα–/– MEFs leads to 
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decreasing of NUMB expression and upregulation of NICD expression accordingly 
(Figure 8B). 
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Fig 7 IKKα, but not IKKβ downregulates NUMB expression  
 
(A) Hep3B and Huh-7 cells were treated with TNFα (20 ng/ml) for 24 h. 
Endogenous NICD and NUMB expression levels were examined by western 
blotting. α-Tubulin was used as loading control. 
 
(B) Hep3B cells were transfected with IKKα and IKKβ. Endogenous NICD and 
NUMB expression was analyzed by western blotting. α-Tubulin was used as 
loading control. 
NICD
IKKβ
IKKα
NUMB
α-TUBULIN
vector       IKKα IKKβ
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Fig 8 Knocking down IKKα impaired TNFα-induced NOTCH1 activation and 
increased NUMB expression 
 
(A) Knockdown of IKKα or double knockdown of IKKα and NUMB by siRNA in 
Hep3B cells. Nontargeting siRNA was used as control. After 24 h of TNFα 
treatment, cell lysates (30 μg) were subjected to western blotting to detect 
endogenous NICD and NUMB expression. α-Tubulin was used as loading control. 
 
(B) Western blot analysis of endogenous NICD and NUMB expression in WT MEFs 
and IKKα–/– MEFs with or without reconstituted IKKα. α-Tubulin was used as 
loading control. 
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CHAPTER 6 IKKα kinase activity is a key factor for TNFα induced NUMB 
suppression and consequent NOTCH1 activation   
 
IKKα is a well-known downstream kinase of TNFα signalling, the next question 
naturally comes out “ does IKKα trigger NUMB/NOTCH1 signalling via its kinase 
activites” Kinase-dead (KD)IKKα mutant, which does not have any kinase activites, 
were introduced into hepatocyte cells. We found not similar to wide type IKKα, 
kinase-dead (KD) IKKα mutant could not downregulate NUMB expression (Figure 
9A), indicating that TNFα/IKKα induce NUMB downregulation and NOTCH1 
activation via IKKα kinase activites. . In addition, RBP-Jk luciferase assay showed 
that overexpression of NUMB could block TNFα-induced NOTCH1 activation 
(Figure 9B). To answer does IKKα-induced NOTCH1 activation functionally affects 
the NOTCH1, we detected transcriptional change of some NOTCH1 downstream 
genes. RNA levels of c-Myc, p21, p27, Hes6, Hey1, and Hey2 were measured via 
real-time PCR with IKKα or NUMB expression. The mRNA levels of NOTCH1 
downstream targets enhanced with IKKα but were decreased in the presence of 
NUMB (Figure 9C). Together, these results indicate that TNFα triggered IKKα 
kinase activity could activate NOTCH1 through NUMB suppression. 
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Fig 9 IKKα functionally effects NOTCH1 activities and suppression NUMB 
 
(A) Hep3B cells were transfected with WT IKKα or KD IKKα. Endogenous NICD 
and NUMB expression was analyzed by western blotting. α-Tubulin was used as 
loading control. 
 
(B) RBP-Jk Luc and NUMB were transfected into Hep3B cells for 48 h. After 
transfection, Hep3B cells were treated with TNFα (20ng/ml) for 24 h. Cell lysates 
were subjected to the luciferase reporter assay. NUMB expression was analyzed 
by western blotting with 10 μg of total lysates. Error bars represent SD (n = 3). * 
indicates statistical significance (P < 0.05). 
 
(C) Hep3B cells were infected with retrovirus expressing IKKα or IKKα and NUMB. 
RNA extracts were purified from the cell lysates and quantitated with real-time PCR. 
The NOTCH1 target gene mRNA levels were normalized to the mRNA levels of 
target genes in vector-infected cells. Error bars represent SD (n = 3). * indicates 
statistical significance (P < 0.05). 
 34
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 35
  
 
 
 
 
 
 
 
 
 
 
 
 
 36
CHAPTER 7 NUMB was transcriptionally regulated by TNFα/IKKα via FOXA2  
 
Since we know NUMB expression could be regulated by TNFα/IKKα, we 
further investigate the underneath molecular mechanism. We first checked the 
status NUMB mNRA using quantitative PCR (qPCR) after TNFα treatment in both 
Huh-7 and Hep3B cells. We found that mRNA of NUMB is decreased with TNFα 
treatment compared those without TNFα treatment (Figure 10A). Next, NUMB 
promoter was analysis to investigate possible candidates of transcriptional 
regulators on NUMB promoter activity. PROMO 8.3 program analysis results 
revealed five types of hepatocyte nuclear factor (HNF) binding sites richly clustered 
on the NUMB promoter (Figure 10B). HNFs are well known transcriptional factors 
involving in a wide spectrum of cell process in multiple human cancers, we further 
investigated whether and which HNFs associates with TNFα/IKKα mediated NUMB 
transcription regulation. Only FOXA2 (HNF3β)-upregulated NUMB mRNA level 
was reduced with IKKα occurrence, indicating that FOXA2-activated NUMB 
transcription can be inhibited by IKKα (Figure 10C). Collectively, these results 
indicate that FOXA2, as a transcriptional factor of NUMB promoter, will decrease its 
transcriptional abilities on NUMB promoter with TNFα, therefore downregulate 
NUMB expression and activation of NOTCH1. 
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Fig 10 NUMB was transcriptionally regulated by TNFα/IKKα via FOXA2  
 
(A) Hep3B and Huh-7 cells were treated with TNFα (20 ng/ml) for 24 h. NUMB 
mRNA level was detected with qPCR. Error bars represent SD (n = 3). * indicates 
statistical significance (P < 0.05). 
 
(B) The TRANSFAC 7.0 and PROMO 8.3 programs were used to predict 
transcriptional factors that bind to the NUMB promoter. Five HNFs were identified 
from the prediction. 
 
(C) Each of the five indicated HNFs was transfected alone or together with IKKα 
into Hep3B cells. NUMB mRNA level was detected with real-time PCR. Error bars 
represent SD (n = 3). * indicates statistical significance (P < 0.05).  
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CHAPTER 8 IKKα Interacts with and phosphorylates FOXA2 in vitro 
 
Based on previous findings, the next coming out question goes to how 
FOXA2 activity was inhibited by IKKα. Since the kinase activity of IKKα involves in 
NUMB suppression and NOTCH1 activation, we first tested the interaction between 
IKKα and FOXA2 in vivo. Reciprocal co-immunoprecipitation showed that IKKα 
physically associated with FOXA2 (Figure 11A). The same protocol were used to 
detect the interaction between endogenous IKKα and FOXA2 using specific 
antibodies against IKKα and FOXA2 (Figure 11B). In addition, In vitro GST or His 
pull-down assays further supported only IKKα, but not  IKKβ, could binds with 
FOXA2 (Figure11C). Based on the physical association between IKKα and FOXA2, 
we examined whether IKKα could phosphorylate FOXA2. GST-FOXA2 was 
phosphorylated by purified recombinant IKKα in in vitro kinase assay. (Figure 11D, 
compare lanes 1 and 2). To further confirm and identified phosphorylation sites on 
FOXA2 by IKKα, we analyzed the kinase assay samples by mass spectrometry 
(MS) and found that FOXA2 was phosphorylated by IKKα at S107 and S111 (Figure 
11E). Mutation of these two sites from serine to alanine abolished IKKα-mediated 
FOXA2 phosphorylation (Figure11D, lane 5). Taken together, these data 
demonstrate that IKKα interacts with and phosphorylates FOXA2 at S107/111 in 
vitro. 
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Fig 11 IKKα Interacts with and phosphorylates FOXA2 in vitro 
 
(A) IKKα and FOXA2 were transfected into 293T cells and analyzed by reciprocal 
co-immunoprecipitation and immunoblotting using indicated antibodies. 
 
(B) Lysates of Hep3B cells were analyzed by reciprocal co-immunoprecipitation 
and immunoblotting using indicated antibodies. 
 
(C) In vitro transcribed FOXA2 proteins (labeled with S35) were incubated with 
commercially available recombinant His-IKKβ and GST-IKKα and then pulled down 
with His/GST beads. IVT: in vitro transcription and translation. S35 concentration in 
cell lysates was determined by film exposure. 
 
(D) FOXA2 phosphorylation was identified by in vitro kinase assay. GST-FOXA2 
was pulled down by GST beads from Hep3B cells and incubated with commercially 
available IKKα for 30 min. 
 
(E) Mass spectrum of FOXA2 phosphorylation sites by IKKα using samples 
(without isotope) from (D). 
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CHAPTER 9 IKKα Interacts with and phosphorylates FOXA2 in vivo 
Although we identified two phosphorylation sites on FOXA2 in vitro, we need to 
further identified IKKα could phosphorylates FOXA2 on these two sites in vivo. 
endogenous FOXA2 were isolated from TNFα treated Hep3B cells to perform MS 
analysis. These two phosphorylation sites were included in other 12 phosphorylate 
sites on FOXA2 with TNFα treatment (Figure 12A). For further investigation, we 
synthesized peptide including 107/111 phosphorylation sites and injected to mouse 
to raise specified mouse polyclonal antibodies against pFOXA2 at S107/111. The 
western immunoblotting assay showed that the antibody recognized specifically 
pFOXA2 (S107/111) phosphorylated by WT IKKα but not by KD IKKα (Figure 12B). 
The pFOXA2 antibody also recognized phosphorylated WT FOXA2 but not the 
double mutant with both serine residues mutated to alanine (FOXA2-SSAA), further 
supporting its specificity (Figure 12C). In addition, the pFOXA2 (S107/111) antibody 
detected pFOXA2 only in the presence of IKKα in an in vitro kinase assay (Figure 
12D). Time course assays to study the effect of TNFα showed that levels of 
pFOXA2 (S107/111) were high at 10–30 min and declined thereafter (Figure 12E), 
consistent with the kinetics of TNFα-induced IKKα activation as measured by 
degradation of IκBα. 
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Fig 12 IKKα Interacts with and phosphorylates FOXA2 in vivo 
 
(A)Hep3B cells were treated with TNFα for 24 h, and cell lysates were analyzed by 
MS to identify in vivo FOXA2 phosphorylation sites. 
 
(B) Hep3B cells were co-transfected with FOXA2 and WT IKKα or KD IKKα. 
pFOXA2 expression was detected using an antibody specific to pFOXA2 
(S107/111). Cell lysates (10 μg) wereloaded for western blotting. 
 
(C) IKKα was co-transfected with WT FOXA2 or FOXA2-SSAA. pFOXA2 
(S107/111) was detected using an antibody specific to pFOXA2 (S107/111). Total 
FOXA2 expression and IKKα expression are also shown. 
 
(D) Western blot analysis of pFOXA2 with an antibody specific to pFOXA2 
(S107/111) using samples (without isotope) from (D). Total FOXA2 expression and 
IKKα expression are also shown. 
 
(E) Hep3B cells were treated with TNFα and harvested at 10, 30, 60, and 120 min 
after treatment. Cell lysates (40 μg) were used for western blot analysis of pFOXA2 
with an antibody specific to pFOXA2 (S107/111). Total FOXA2 expression and 
IKKα expression are also shown. 
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CHAPTER 10 IKKα phosphorylates FOXA2 in nucleus 
Previous reports showed that response to TNFα, IKKα would translates from 
cytoplasm to nucleus and regulate its downstream target transcriptionally or 
translationally. To identify the subcellular location of FOXA2, IKKα before and after 
TNFα treatment, we perform cell fraction to identify the expression level of both 
proteins in different cell parts. We treated IKKβ–/– MEFs with TNFα and isolated the 
nuclear and cytoplasmic fractions from the cells for immunoprecipitation by the 
IKKα antibody. We found that stimulation of IKKβ–/– MEFs with TNFα increased 
nuclear accumulation of IKKα, the amount of FOXA2 bound to IKKα, and 
phosphorylation of FOXA2 (S107/111). However, we did not detect either pFOXA2 
or FOXA2 expression in the cytoplasm after TNFα treatment, suggesting that TNFα 
increased the nuclear accumulation of IKKα which phosphorylates FOXA2 in 
nucleus. (Figure 13) 
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Fig 13 IKKα phosphorylates FOXA2 in nucleus 
 
IKKβ–/– MEFs were treated with TNFα for 45 min. Cell lysates were subjected to cell 
fractionation. After immunoprecipitation by the IKKα antibody, the nuclear and 
cytoplasmic fractions were subjected to western blot analysis with indicated 
antibodies. Lamin and tubulin were used as cell fractionation controls. 
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CHAPTER 11 FOXA2 Phosphorylation by IKKα Suppresses FOXA2 
transactivation Activity 
Since upon TNFα stimulation, IKKα phosphorylates FOXA2 and leads to 
NUMB suppression, it is possible that FOXA2 lost its function as a transcriptional 
factor after being phosphorylated by IKKα, therefore leads to the suppression of 
NUMB and consequently NOTCH1 pathway enhancement. To test this hypothesis, 
we constructed a plasmid containing FOXA2-responsive elements (FRE) to drive 
the luciferase reporter, which could mimic FOXA2 downstream gene promoter 
activites and monitor the FOXA2 transactivation activity in general. After we 
introduced it to 293T cells, we found that WT IKKα could suppress FOXA2 
transactivation activity, but the activity would not be affected by KD IKKα (Figure 
14A). The similar results represents in luciferase reporter assay used a plasmid 
containing. a 1kb key promoter of NUMB which drives luciferase reporter gene to 
detect NUMB promoter activities with or without IKKα effects (Figure 14B).  
To test whether IKKα suppression activities on FOXA2 comes from the two 
specific phosphorylation sites on FOXA2 (S107/111), we double mutated the two 
critical Serine amino acids to either Alanine or Glutamine, which mimic the 
nonphosphorylated and phosphorylated state of FOXA2. The NUMB promoter 
drived luciferase reporter assay showed that FOXA2-SSEE could not activate 
NUMB promoter activities comparing to WT FOXA2, but the present of 
FOXA2-SSAA has the similar transactivation activities to WT FOXA2. (Figure 14C) 
In addition, Unlike WT FOXA2, FOXA2-SSEE and FOXA2-SSAA maintained their 
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transactivation activities regardless the status of IKKα, suggesting that 
phosphorylation of FOXA2 at S107/111 is the major factors to effect FOXA2 
transactivation activity (Figures 14C and 14D). These results support that IKKα 
decreased FOXA2 transactivation activity by phosphorylating FOXA2 at S107/111. 
To detect whether the reduction transactivation activities of FOXA2 is the reason 
for the suppression of NUMB expression with TNFα treatment, we examined the 
NUMB mRNA level by transfecting various FOXA2 constructs expressing WT 
FOXA2, FOXA2-SSAA, FOXA2-SSEE, or vector control into Hep3B cells. As 
expected, FOXA2-SSAA, but not FOXA2-SSEE, enhanced NUMB mRNA level 
(Figure 14E). These results further support the notion that S107/111 
phosphorylation inhibits FOXA2 transactivation activity. 
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Fig 14 FOXA2 Phosphorylation by IKKα Suppresses FOXA2 transactivation 
activity 
 
(A) Six repeated consensus binding sites of FOXA2 were constructed into 
Luc-driven reporter (FRE-Luc). NUMB promoter luciferase reporter and FOXA2 in 
the presence of different doses of WT IKKα or KD IKKα were transfected into 293T 
cells for 48 h. Cell lysates were subjected to luciferase reporter assays after 
transfection. The luciferase activities were normalized to mock cells with NUMB 
promoter luciferase reporter. Error bars represent SD (n = 3). * indicates statistical 
significance (P < 0.05). 
 
(B) NUMB promoter luciferase reporter and FOXA2 in the presence of different 
doses of WT IKKα or KD IKKα were transfected into 293T cells for 48 h. Cell 
lysates were subjected to luciferase reporter assays after transfection. Expression 
levels of WT IKKα, KD IKKα, and FOXA2 were analyzed by western blotting. Error 
bars represent SD (n = 3). * indicates statistical significance (P < 0.05). 
 
(C) Co-transfection of NUMB-promoter Luc and WT FOXA2, FOXA2-SSAA, or 
FOXA2-SSEE plus the indicated Flag-tagged IKKα in 293T cells for 48 h. Lysates 
of 293T cells were subjected to luciferase assays. Error bars represent SD (n = 3). 
* indicates statistical significance (P < 0.05). Expression levels of IKKα, WT FOXA2, 
and FOXA2 mutants were detected by western blot analysis. 
 
(D) Co-transfection of FRE-Luc and WT FOXA2, FOXA2-SSAA, or FOXA2-SSEE 
plus the indicated Flag-tagged IKKα in 293T cells for 48 h. Lysates of 293T were 
subjected to luciferase assays. Error bars represent SD (n = 5). * indicates 
statistical significance (P < 0.05). 
 
(E) Hep3B cells were infected with retrovirus expressing FOXA2-SSAA or 
FOXA2-SSEE. RNA extracts from the cells were isolated and subjected to 
real-time RT-PCR for NUMB mRNA expression. Error bars represent SD (n = 3). * 
indicates statistical significance (P < 0.05). 
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CHAPTER 12 FOXA2 Phosphorylation by IKKα decreases FOXA2 DNA 
binding activities 
 
Since we know that FOXA2 transactivation activities decrease after being 
phosphorylated by IKKα, the further question naturally comes to the underneath 
molecular mechanism involving in the inhibition activities. The DNA binding ability 
is a crucial factor to influent transactivation activities of transcriptional factors, we 
first examined the difference in the binding ability of FOXA2 to the NUMB promoter 
before and after TNFα treatment. We performed a chromatin immunoprecipitation 
(ChIP) assay using primers spanning the putative FOXA2 binding sites (see primer 
sequences in the Experimental Procedures section) in the NUMB promoter from 
Hep3B cell lysates with or without TNFα treatment. We found that binding of 
FOXA2 to the NUMB promoter was decreased by TNFα (Figure 15A, to left of 
arrow). In addition, we compared the binding ability of WT FOXA2, FOXA2-SSAA, 
and FOXA2-SSEE to the NUMB promoter by ChIP and found that WT FOXA2 and 
FOXA2-SSAA, but not FOXA2-SSEE, bound to the NUMB promoter (Figure 15B), 
suggesting that FOXA2 phosphorylation by IKKα suppressed FOXA2 
transactivation activity on NUMB by decreasing FOXA2 accessibility to its promoter. 
We further tested the function of FOXA2-SSAA and FOXA2-SSEE in 
FOXA2-knockdown Hep3B cells. The western immunoblotting assay showed that 
both WT FOXA2 and FOXA2-SSAA stimulated NUMB protein level (Figure 15C). 
WT FOXA2 expression could suppressed NUMB enhancement with TNFα 
 57
stimulation, (Figure 15C, compare lanes 2 and 6) but FOXA2-SSAA has no effect 
on FOXA2 –induced NUMB enhancement (compare lanes 3 and 7). Moreover, 
FOXA2-SSEE has no response to TNFα treatment (lane 8), suggesting that 
phosphorylation of FOXA2 on S107/111 is the major reason for suppression the 
FOXA2 associated NUMB expression. The results of monitoring NOTCH1 activities 
by RBP-Jk luciferase reporter assay showed the FOXA2-associated NOTCH1 
suppression could be released by mimic phosphorylated FOXA2-SSEE (Figure 
15D). Collectively, our results indicate that S107/111 phosphorylation of FOXA2 by 
IKKα limit the FOXA2 DNA binding ability, leads to less FOXA2 transactivation 
activities on NUMB promoter, therefore suppress NUMB promoter activities, NUMB 
mRNA level and protein expression, and triggers NOTCH1 signalling as a results. 
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Fig 15 FOXA2 Phosphorylation by IKKα decreases FOXA2 DNA binding 
activities 
 
(A) Hep3B cells were treated with TNFα for 24 h, and cell lysates were harvested 
and subjected to primary ChIP assay using the FOXA2 antibody. The purified DNA 
from the ChIP assay was subjected to real-time PCR using NUMB primers (to left 
of arrow). Error bars represent SD (n = 3). * indicates statistical significance (P < 
0.05).  
 
(B) Endogenous FOXA2 in Hep3B cells was knocked down by shRNA against the 
5′-UTR. After shRNA knockdown of FOXA2, we transfected WT FOXA2, 
FOXA2-SSAA, or FOXA2-SSEE into FOXA2–/– Hep3B cells, followed by TNFα 
treatment for 24 h. Cell lysates were analyzed by western blotting using indicated 
antibodies. 
 
(C) RBP-Jk Luc and WT FOXA2, FOXA2-SSAA, or FOXA2-SSEE were 
co-transfected into Hep3B cells for 24 h, followed by TNFα treatment for 24 h. Cell 
lysates were analyzed by luciferase reporter assay. Error bars represent SD (n = 3). 
* indicates statistical significance (P < 0.05).  
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CHAPTER 13 FOXA2 Phosphorylation by IKKα De-Represses 
FOXA2-Mediated Repression of Cell Growth In Vitro 
 
Previous reports showed that NUMB and NOTCH1 pathway involves in cell 
proliferation in many type of cancers, we next to test if IKKα-induced FOXA2 
phosphorylation associates with cell proliferation and growth in HCC cells. We 
examined the function of non-phosphorylation FOXA2, phosphorylation FOXA2 
and WT FOXA2 in cell growth by 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. We 
found that both FOXA2-SSAA and WT FOXA2 would inhibit cell growth compared 
to control or FOXA2-SSEE cells (Figure 16A). In addition, WT IKKα, but not KD 
IKKα, showed the ability to recovered Hep3B cells growth suppression from WT 
FOXA2 expression, presumably as a result of phosphorylation of WT FOXA2 by 
IKKα, which leads to loss function of FOXA2 in terms of inhibition of cell growth. 
(Figure 16D). Knocking down NUMB reversed the cell growth inhibition by WT 
FOXA2 and FOXA2-SSAA, supporting our proposed suppressive role of NUMB in 
the TNFα/IKKα pathway (Figure 16B). To verify that NOTCH1 activation is the main 
reason leading to cell growth in this TNFα/IKKα triggered pathway, we knocked 
down NOTCH1 in Hep3B cells to monitor cell growth in MTT assay. The results 
showed that Hep3B cell growth was inhibited after NOTCH1 knockingdown 
regardless of FOXA2 phosphorylation status, demonstrating that NOTCH1 
signaling activation was the major reason for the TNFα/IKKα induced cell growth 
(Figure 16C). We also use two NOTCH1 pathway inhibitors, LY-411575 and 
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γ-secretase inhibitor (GSI) to block NOTCH1 pathway in different liver cancer cell 
lines to detect the influence on cell growth by counting cell numbers. The results 
showed that after NOTCH1 inhibitors treatment, the cell growth of all liver cancer 
cell lines decreased, further supporting that NOTCH1 activation plays an important 
role in liver cancer cell growth (Figure 16E). Consistent with MTT results, 
FOXA2-SSAA inhibited cell colony formation in an anchorage-independent growth 
assay (Figure 19F upper). Without NUMB expression would significantly increase 
colony formation no matter what the status of FOXA2. (Figure 16F bottom). When 
NOTCH1 was knocked down, colony formation was diminished which is consistent 
to cell growth (Figure 16G bottom). 
To verify the status of DNA synthesis under these conditions, we also 
performed a bromodeoxyuridine (BrdU) incorporation assay. We found the similar 
results to MTT assay and anchorage-independent growth assay. (Fig 16 H, I) 
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Figure 16 FOXA2 Blocks IKKα-Induced Cell Proliferation and Tumor Growth 
In Vitro 
 
(A, B, and C). Hep3B cells were infected with retrovirus expressing WT FOXA2, 
FOXA2-SSAA, or FOXA2-SSEE in the presence of (A) control shRNA, (B) NUMB 
shRNA, or (C) NOTCH1 shRNA. Cells (2.5 × 103) were plated in 96-well plates, and 
cell growth was determined by MTT assay each day for 4 days. 
 
(D) WT IKKα or KD IKKα was co-transfected with GFP-tagged WT FOXA2, 
FOXA2-SSAA, or FOXA2-SSEE into Hep3B cells. After 48 h, GFP-positive cells 
were sorted by flow cytometry. Sorted cells were seeded in 96-well plates at 
5000/well and subjected to MTT assay. Error bars represent SD (n = 3). * indicates 
statistical significance (P < 0.05).  
 
(E) Huh-7, HepG2, Hep3B, PLC/PRF/5, HA22T/VGH, HA59T/VGH, Mahlavu, 
Tong/HCC, and SK-Hep-1 cells were serum-starved for 24 h and then treated with 
LY-411575 (250 μM), GSI (10 μM), or DMSO for 48 h. After treatment, cells were 
counted with a Beckman Coulter cell counter.  Error bars represent SD (n = 5).  
(F.and G). Anchorage-independent growth assay of Hep3B cells infected with 
retrovirus expressing WT FOXA2, FOXA2-SSAA, or FOXA2-SSEE in the presence 
of (F) NUMB shRNA or (G) NOTCH1 shRNA, compared with control shRNA. 
Colony numbers (mean ± SD) in week 3 are shown (n = 6). * indicates statistical 
significance (P < 0.05, Student’s t test). Representative images from the 
anchorage-independent growth assay are shown below. 
 
(H) KD IKKα inhibited Hep3B cell proliferation. WT FOXA2, FOXA2-SSAA, or 
FOXA2-SSEE and WT IKKα or KD IKKα were co-transfected into Hep3B cells. 
After 48 h, cells were subjected to BrdU assay and analyzed by flow cytometry. 
(I) Hep3B cells were infected with retrovirus expressing WT FOXA2, FOXA2-SSAA, 
or FOXA2-SSEE either without (top) or with (bottom) NUMB shRNA. Infected cells 
were subjected to BrdU assay and analyzed by flow cytometry. 
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CHAPTER 14 FOXA2 Phosphorylation by IKKα De-Represses 
FOXA2-Mediated Repression of Cell Growth In Vivo 
The tumor promotion functions of IKKα-induced FOXA2 phosphorylation were 
further confirmed in mouse model. We injected Hep3B cells into three groups of 
nude mice using an orthotopic liver cancer animal model (Xiong, et al., 2010). We 
monitored the tumor volume (TV) of these mice for 6 weeks and analyzed tumor 
tissue samples by western blotting. To determine the role of IKKα in liver tumor 
growth, we injected the first group of mice with Hep3B cells infected with retrovirus 
expressing shRNA against IKKα. TV was much smaller in the mice harboring 
tumors (after transplantation) than in the control group, validating the role of IKKα in 
liver tumor growth (Figure 17A). Western blot analysis of these tumor tissue 
samples detected TNFα in tumors along with decreased FOXA2 phosphorylation, 
enhanced NUMB expression, and attenuated NICD expression (Figure 71B). The 
second group of mice was injected with cells infected with retrovirus expressing WT 
or mutant FOXA2, and transplantation was performed essentially as described for 
the first group. We found that WT FOXA2 and FOXA2-SSAA both inhibited tumor 
growth, whereas FOXA2-SSEE had no effect (Figure 17C, top). In addition, NUMB 
expression was increased with a decrease in NICD expression in the WT FOXA2 
and FOXA2-SSAA tumors (Figure 17C, bottom). Together, these results suggest 
that FOXA2-SSAA functions in a dominant manner to inhibit tumor growth and 
support the importance of IKKα in promoting FOXA2-associated HCC 
development. 
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Previously, we showed that knockdown of NUMB increased cell growth rate 
and colony formation regardless of FOXA phosphorylation status. To demonstrate 
the role of NUMB in TNFα/IKKα-induced tumor growth in vivo, we knocked down 
NUMB by shRNA in Hep3B cells infected with retrovirus expressing WT FOXA2 
and its mutants. Mice that received transplanted tumors harboring these 
NUMB-knockdown cells continued to show tumor growth even in the presence of 
FOXA2 and FOXA2-SSAA, which was probably due to restored NICD expression 
and is consistent with results from the in vitro assays (Figure 17D, bottom). 
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Figure 17. FOXA2 Blocks IKKα-Induced Cell Proliferation and Tumor Growth 
In Vivo 
 
(A) Hep3B cells were infected with retrovirus expressing control or IKKα shRNA. 
Mice were injected subcutaneously with 1 × 106 cells. Error bars represent SD (n = 
5). Please see the Experimental Procedures section for more detailed information. 
  
(B) Tumor tissues from mice that received transplants were analyzed 10 days after 
transplantation and subjected to western blot analysis for indicated antibodies. 
Right: Expression levels of pFOXA2, NUMB, and NOTCH1 quantified with ImageJ 
software. 
 
(C) Hep3B cells were infected with retrovirus expressing WT FOXA2, 
FOXA2-SSAA, or FOXA2-SSEE in the presence of (top) control shRNA or (bottom) 
NUMB shRNA. Error bars represent SD (n = 5). Please see the Experimental 
Procedures section for more detailed information. 
 
(D) Tumor issues from (C) were harvested 10 days after transplantation and 
subjected to western blot analysis for NICD, FOXA2, and NUMB. α-Tubulin was 
included as control. 
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CHAPTER 15 FOXA2 Phosphorylation by IKKα play roles in liver cancer 
 
In addition, to further examine the aforementioned conclusion that FOXA2 
phosphorylation by TNFα-induced IKKα plays a critical role in liver cancer, we 
examined the expression of IKKα, pFOXA2 (S107/111), and NICD in 30 freshly 
prepared human primary HCC tumor specimens and paired normal liver tissues by 
immunoblotting. We found that IKKα, pFOXA2 (S107/111), and NICD expression 
levels were significantly higher in tumor specimens than in the corresponding 
normal liver tissues (P < 0.05) (Figures 18A, 18B). In addition, pFOXA2 expression 
was positively correlated with expression of IKKα and NICD. These results 
strengthen the notion that IKKα regulates FOXA2 and activates NICD through 
phosphorylation at S107/111 and the physiological implication of pFOXA2 in 
IKKα-induced tumorigenesis (18C, 18D). Taken together, analyses of these clinical 
HCC tumor specimens support that FOXA2 phosphorylation by IKKα might be 
associated with HCC tumorigenesis. 
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Fig 18 FOXA2 Phosphorylation by IKKα play roles in liver cancer 
 
(A, B) Comparison of pFOXA2 (S107/111), IKKα, and NICD expression in tumors 
and their adjacent normal tissues. Protein expression was examined by 
immunoblotting 30 pairs (tumor and normal) of liver tissue samples and quantified 
with ImageJ software. Right: Four representative pairs (N, normal; T, tumor). 
Protein expression levels in tumor samples were normalized to those in paired 
normal tissues. Protein expression levels higher (or lower) than those in normal 
tissues were defined as “high” (or “low”).(P < 0.01, Pearson’s chi-square test.) 
 
(C, D) Correlation analysis of pFOXA2 and IKKα/NICD expression levels in tumors 
(R2 > 0.5, Spearman’s rank correlation test). 
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CHAPTER 16 Summary & Discussion 
Summary 
Here, we identified an axis in TNFα pathway involving activation of NOTCH1 
signaling through suppression of FOXA2 transactivation activity by IKKα, leading to 
disruption of NUMB expression, which promotes NOTCH1-induced liver cell 
proliferation and growth. In our proposed model, TNFα-activated IKKα interacts 
with and phosphorylates FOXA2. We identified two IKKα-mediated FOXA2 
phosphorylation sites, Ser107 and Ser111. Phosphorylation at these two sites 
decreased FOXA2 transactivaction activities, reduced the expression of a FOXA2 
downstream target gene, NUMB, and subsequently, increased tumor growth. 
Analysis of HCC patient tumor tissue samples suggests that phosphorylation of 
FOXA2 on Ser 107/111 residues could be a new marker for detecting 
inflammation-induced liver cancer.  
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Fig 19  Model of TNFα induced FOXA2/NOTCH1 pathway  
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Discussion 
Inflammation, TNFα and Liver Cancer: 
It is not surprise to see inflammation has a tight relationship to human cancers. In 
our daily life, food factors, stress, environmental pollution, bacteria and viruses 
could increase expression of chemokines and cytokines, including TNFα. The 
enhancement of chemokines and cytokines will further induce acute inflammation 
and chronic inflammation. Almost all acute inflammations are responded quickly by 
human innate immunity system. Chronic inflammation will turns to increase the 
potential possibilities of cancer in certain organs. 
As one of the most important cytokines, TNFα has a large amount of activities in 
cell to cell communications and inflammation-associated human cancers. 
Dysregulation of TNFα signaling pathway contributes to the development of human 
cancers due to enhanced IKK complex activity and regulate NF-κB downstream 
oncogenic target genes including cytokines, chemokines, enzymes, survival genes 
and some of angiogenesis factors. There are several mouse model were set up 
which could provide more evidence for the role of TNFα in cancers, especially in 
liver cancer. 
The most direct evidence to show the tumor-promoting role of TNFα was 
similarly investigated in models of hepatic carcinogenesis. TNFRI-/- mice displayed 
reduced oval cell (hepatic stem cell) proliferation during the pre-neoplastic phase of 
liver carcinogenesis, correlating with fewer tumours than wild-type mice 
In addition, one of the most famous liver cancer mouse models is 
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DEN-induced hepatocarcinogenesis model Dr. Michael Karin, who has previously 
set up the DEN system, indicated in some of his papers that the DEN-induced 
hepatocarcinogenesis model is “TNF-independent”. Data from these papers 
showed that upon DEN induction, the tumor multiplicity and maximum size of the 
lack of TNFR1 (TNFα receptor) mouse has no significant difference to those of wild 
type mouse, indicating TNFα signaling is not required for DEN-induced 
hepatocarcinogenesis.  
Another model related to TNFα/IKK roles in liver cancer is the Mdr2-KO mouse 
model, It is an inflammation-associated model of HCC, which is directly linked to 
NF-κB. The Mdr2-KO mouse system was engineered Dr. Yinon Ben-Neriah, who 
showed that NF-κB functions as a tumor promoter in inflammation-associated liver 
cancer by anti-TNFα treatment or ectopic expression of an IκB-super-repressor 
transgene (Pikarsky, 2004). To the best of our knowledge, an independent role of 
IKK complex unit in Mdr2-KO mouse has not been reported yet. It would be of 
interest to test our findings in this Mdr2-KO mouse system. 
 
NOTCH1 and Cancers 
We demonstrate that TNFα also stimulates the NOTCH1 pathway in liver cancer 
cell lines. Previous studies have reported that NOTCH1 has two different roles, one 
that promotes and the other that suppresses tumorigenesis. Which of the two roles 
is going to be dominant is dependent on the cellular context and the crosstalk with 
other signal-transduction pathways.  
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Although NOTCH1 has been shown to play a role as an oncogene in mainly 
in leukemia and breast cancer, one report demonstrated inhibition of HCC tumor 
growth through NOTCH1 signaling by induction of cell cycle arrest and apoptosis114. 
Several groups that analyzed clinical samples of human HCC also indicate a 
positive role of NOTCH1 in liver cancer115-117. More recently, Ning et al. specifically 
showed downregulation of NOTCH1 signaling inhibited tumor growth in human 
HCC in both cell lines and mouse model118. These studies are in line with our 
findings that NOTCH1 is activated by TNFα through deregulation of FOXA2 
transactivity to promote cell proliferation and growth.  
NOTCH1 signaling plays an oncogenic role in a majority of solid tumors, and 
thus, NOTCH1 inhibition may represent a viable treatment for cancer. So far, the 
best-developed tool for NOTCH1 signaling inhibition is a small molecule inhibitor of 
γ-secretase. In clinical trial, γ-secretase inhibitor for cancer therapy faced 
challenges for its high cytotoxicity and non-specific targeting48. 
 
FOXA2 proteins and Cancers 
Some FOX subfamilies such as FOXO, FOXM, FOXP, FOXC, and FOXA 
have been linked to tumorigenesis and the progression of certain cancers. For 
instance, the loss of FOXA2 activity may increase EMT in both lung cancer and 
pancreatic cancer119-120. IN addition, FOXA2 proteins are found to be a key 
regulator in lung inflammation38. In our model, we showed that a new FOX family 
member plays important role in inflammation-induced liver cancer. FOXA2 is a 
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transcriptional factor that binds to the NUMB promoter in both genome-wide screen 
and software analysis. FOXA2 recently We showed that phosporylation of FOXA2 
by IKKα resulted in the loss of FOXA2 transactivation activity and decreased its 
binding capacity to the NUMB promoters, and therefore, activates NOTCH1 
pathway. The crystal structure of FOXA2 DNA binding domain was published in 
1993; however, the crystal structure of full-length of FOXA2 is not yet available. 
The phosphorylation sites that we identified (S109/111) are located in domain 
between TAD and WHD. The results from the CHIP assay suggested that 
phosphorylation on Ser 109/111 decreased the ability of FOXA2 to associate with 
the NUMB promoter. In addition, FOXA2 is known to associate with some 
promoter-associated factors such as TBP (TATA Box binding protein), HNF6, and 
the other two FOXA family members, FOXA1 and FOXA3. At this moment, it is not 
clear and would require further investigation to determine how phosphorylation of 
Ser 109/111 affects DNA-binding activity and/or its interaction with other 
transcription factors.  
In summary, the identification of FOXA2 as a downstream substrate of IKKα 
links the TNFα and NOTCH1 signaling pathways and provides an important new 
starting point for uncovering the molecular basis of TNFα-mediated human tumor 
growth and identifying potential targets for cancer therapy. Inhibition of FOXA2 
phosphorylation or activation of NUMB could have important clinical implications for 
the treatment or prevention of cancer.  
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FUTURE DIRECTION 
We previously found that phosphorylation of FOXA2 by IKKα induces tumorigenesis 
through activating NOTCH pathway in a cell culture system and an orthotopic 
mouse model, but the in vivo role of these phosphorylations in tumorigenesis is still 
nebulous. In recent years, the use of knock-in technology to clarify the role of 
phosphorylation of specific kinase targets in vivo has emerged as a valuable tool for 
assessing the organism-wide importance of these signaling events49-51. Thus, we 
will apply this strategy to engineer two phosphorylation mutants in the FoxA2 
genetic locus (FoxA22A/2A and FoxA22E/2E knock-in alleles) to clarify the importance 
of IKKα/FoxA2 signaling pathway in tumor progression. 
 
Aim 1: Generate and characterize FoxA22A/2A and FoxA22E/2E knock-in mice. 
Rationale: We previously found that phosphorylation of FOXA2 by IKKα induces 
tumorigenesis through activating NOTCH pathway in a cell culture system and an 
orthotopic mouse model [43], but the in vivo role of these phosphorylations in 
metabolism and tumorigenesis is still nebulous. In recent years, the use of knock-in 
technology to clarify the role of phosphorylation of specific kinase targets in vivo has 
emerged as a valuable tool for assessing the organism-wide importance of these 
signaling events[21-23]. In this aim, we will apply this strategy to FoxA2 and will 
engineer two mutants from the FoxA2 genomic locus (FoxA22A/2A and FoxA22E/2E 
knock-in alleles) to clarify the importance of IKKα/FoxA2 signaling pathway in tumor 
progression. 
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Experimental design  
a. Mouse embryonic stem cell targeting. The knock-in targeting construct 
contains FoxA2 exons 1-3 and the neomycin selection cassette. The approach is 
outlined in Figure 2 and described briefly here. The targeting construct will be 
amenable to site-directed mutagenesis of the IKKα phosphorylation sites for Ser107 
and Ser111, which will be mutated to encode alanin (A) or glutamic acid (E), and for 
the insertion of a 2-kb floxed neomycin-resistance (Neo) cassette which allows 
selection in both bacteria(on kanamycin) and in embryonic stem(ES) cells (on 
neomycin/G418), into a unique XhoI site. The targeting construct will be provided to 
The University of Texas M. D. Anderson Cancer Center Genetically Engineered 
Mouse Facility (a core institutional resource) for ES cell targeting and neomycin 
selection. We will screen Neo-positive clones for proper integration of the Neo 
cassette and the two point mutations by Southern blot analysis with 5’ and 3’ probes 
directed to the FoxA2 transgene in transgenic progenies. To remove the floxed Neo 
cassette, FoxA2+/2A or FoxA2+/2D ES cells will be transfected with pMC-CrePuro, 
which encodes for Streptomyces alboniger puromycin-N-acetyl-transferase and Cre 
recombinase, and selected in medium containing puromycin. Selected clones will 
be picked up and subjected to polymerase chain reaction (PCR) analysis using 
primers P1 (5’-CAAAACAAAACCAACTAACC-3’) and P2 
(5’-GTAATTCTTTCCTGTCCCTG-3’). These primers result in a 324-bp product from 
the wild-type allele and a 413-bp product from the targeted allele after the neomycin 
cassette has been excised (Figure 20). After several independent strains of 
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transgenic mice expressing either FoxA2-2A or FoxA2-2D have been generated, we 
will choose two independent lines for our further studies.  
 
 
 
          
 
 
 
 
 
 
Fig 20 A diagram of knock-in strategy of the FoxA22A/2A and FoxA22E/2E allele  
 
b. Generation of chimeric and FoxA22A/2A and FoxA22E/2E mice. Heterozygous 
knock-in FoxA2+/2A and FoxA2+/2D ES cell clones will be microinjected into C57BL/6J 
blastocysts, which will be then re-implanted into recipient female mice with the 
assistance of the M. D. Anderson Cancer Center Genetically Engineered Mouse 
Facility. Chimeric mice with a high degree of ES-cell contribution will be identified by 
coat color and then crossed to 129/SvJae mice. This allows germline transmission 
of the knock-in allele to be identified by the grey coat of the resulting pups. Multiple 
chimeric offspring will be obtained and bred with wild-type C57BL/6J mice to 
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Endogenous  allele
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produce F1 animals. Genotyping of FoxA2+/2A and FoxA2+/2D mice will be carried out 
by PCR of genomic DNA isolated from tails or embryonic membranes. Primers P1 
and P2, originally used to screen cells for the excision of the neomycin cassette, will 
be used to genotype the mice. Homozygous knock-in FoxA22A/2A and FoxA22E/2E 
mice will be generated by crossing FoxA2+/2A mice with FoxA2+/2A mice and 
FoxA2+/2D mice with FoxA2+/2D mice, and the resulting pups will be genotyped by 
PCR.   
 
c. Phenotypic analyses of FoxA22A/2A and FoxA22E/2E mice. Once a knock-in line 
is established, we will first assess any developmental defects in the FoxA22A/2A and 
FoxA22E/2E mice by assessing the genotypes of offspring from the various crosses. If 
embryonic lethality is observed for either of these genotypes, we will determine the 
developmental stage at which the mice die and assess the defects leading to 
mortality. Viability of FoxA22A/2A and FoxA22E/2E mice will show that this mutant 
FoxA2 allele is functional in vivo, as FoxA2-/- death at E10-11. If no lethality is 
observed for either FoxA22A/2A or FoxA22E/2E knock-in mice, we will use FoxA22A/2A 
and FoxA22E/2E knock-in mice for further phenotypic characterization in which 
cohorts of mice (20 of each genotype, 10 males and 10 females) will be killed at 6 
and 12 months of age and sent to the M. D. Anderson Department of Veterinary 
Medicine and Surgery for full necropsy. Necropsy analysis will include examination 
and sectioning of brain, intestines, heart, lungs, thymus, kidneys, spleen, skeletal 
muscle and liver, and organs will be cut into dorsoventral sections for histologic 
 87
examination by standard H&E staining. We will also keep a cohort of FoxA22A/2A and 
FoxA22E/2E littermates (20 of each genotype, 10 males and 10 females) for survival 
and longevity studies. 
 
Expected outcomes: Our previous in vitro study demonstrated that FoxA2 mutants 
lacking IKKα phosphorylation sites can dominantly impair FoxA2 downstream target 
gene activation. Because FoxA2 target genes are essential for early development in 
mammals, it is possible that both FoxA22A/2A and FoxA22E/2E mice will exhibit early 
developmental defects and embryonic lethality. It remains to be seen if this kind of 
regulation for FoxA2 is critical during mammalian development. If embryonic 
lethality is seen for either FoxA22A/2A or FoxA22E/2E mice, we will characterize the 
cause of death in detail. Otherwise, we expect that heterozygous FoxA22E/2E mice 
will develop polyps or intestinal lesions due to suppressed FOXA2 activity. A mild 
inflammation which is associated with tumors may occur.  
 
Possible experimental problems and alternative approaches: FoxA2 tumor 
related function may affect tumor origination or tumor development or both. If 
phosphorylation of FoxA2 by IKKα promoting but not initiating the tumor 
development, we may not see tumor in previous mouse model. If it is the case, we 
will alter to cross Apc716/+ mice (a mouse model of liver tumorigenesis) with our 
knock-in mouse to see if FoxA22A/2A inhibit and FoxA22E/2E activate tumor 
progression in Apc716/+ mice. 
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Aim 2: Investigate FOXA2 downstream target gene inactivation, cell 
proliferation and tumor development in FoxA22A/2A and FoxA22E/2E knock-in 
mice. 
Rationale: Because the TNFα/IKKα signaling pathway, which regulates FOXA2 
downstream target genes inactivation through the inhibition of FOXA2 and 
culminates in cell growth, has been studied only in vitro [43], it remains unclear 
whether this pathway affects FOXA2 downstream target gene inactivation, cell 
metabolism, cell proliferation and tumor development in vivo. Thus, we propose to 
determine whether FoxA22E/2E mice (in which FOXA2 is inactivated) show abnormal 
target gene activation, metabolism disorder, cell proliferation, and tumor 
development relative to wild-type mice or FoxA22A/2A mice (in which FOXA2 is 
constitutively activated). 
  
Experimental design: Different organs (including brain, intestine, heart, lungs, 
thymus, kidneys, spleen, skeletal muscle and liver) of FoxA2+/+, FoxA22A/2A and 
FoxA22E/2E mice will be dissected for assessment of typical FOXA2 downstream 
target genes and NOTCH pathway marker (like c-myc, hes-1) by immunostaining. 
The offspring of 20 litters (a target of at least 90 mice in total) will also be analyzed 
for tumor development. Briefly, a cohort of FoxA22A/2A and FoxA22E/2E littermates (20 
of each genotype, 10 males and 10 females) will be killed at 12 and 18 months of 
age and sent to the M. D. Anderson Department of Veterinary Medicine and Surgery 
for full necropsy and tumor examination.  
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Expected outcomes: We expect to see that organs from FoxA22E/2E mice (with 
inactivated FoxA2) will show higher expression of NOTCH pathway marker, like 
Hes-1, Hey-6, c-Myc and less expression in FOXA2 target genes, like Numb, Gcg, 
than FoxA2+/+ or FoxA22A/2A mice. Moreover, we may find that FoxA22E/2E mice have 
a greater potential to develop various types of colorectal cancers compared with the 
FoxA2+/+ and FoxA22A/2A mice. If using combination model of FoxA22E/2E×Apc716/+, 
we expect to see the tumor growth in FoxA22E/2E×Apc716/+ mice will be larger than 
that in Apc716/+ parental mice.  
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